Fresh analysis indicates that patients who discontinue new weight-loss injections like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt conventional diet and exercise regimens.
Findings released in a major health publication points out that while obese individuals often shed about a fifth of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"Users buying these drugs should be aware of the risk of rapid weight regain when the medication is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to original weight within about one and a half years.
Weighing Treatments
The research, which reviewed 37 of studies involving over 9,000 of participants, compared the results of GLP-1 agonists with conventional dieting.
Scientists note that people who shed pounds through dieting usually experience a slower weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Doctors believe the mode of action of the jabs is key to understanding the amplified regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Artificially providing the hormone levels far above than normal may cause the system to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication results in hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Condition?
Health authorities advise the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians say that, due to the likelihood of weight regain, the treatment should be considered life-long.
This view is echoed by drug manufacturers, who note that the results "underscore the chronic character of excess weight," akin to managing diseases like high blood pressure.
User Experiences
Users who have discontinued the medication describe a sudden resurgence of hunger.
"It felt as if something flipping and I was suddenly starving," said one woman.
This difficulty is compounded if individuals have not established sustainable lifestyle or habit changes during treatment.
Growing Use
Figures show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is more common among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, experts caution that while the jabs are powerful tools for shedding pounds, they are not a standalone cure and maintained weight loss hinges on combined lifestyle changes.
